Cetiedil citrate 

Cetiedil citrate is a vasodilator and antihemolytic agent. Cetiedil citrate exerts anti-sickle cell anemia effects by blocking Ca²⁺-activated K⁺ channels (Gardos/KCa3.1). Cetiedil citrate is a muscarinic receptor antagonist that inhibits calcium-dependent release of acetylcholine (ACh) from mediated reconstituted proteoliposomes, with a K_i value of 5 μM. Cetiedil citrate possesses analgesic, spasmolytic and local anesthetic activities. Cetiedil citrate can be used in research related to ischemic leg pain caused by vascular diseases and sickle cell disease^[1][2][3].

Cetiedil (10-50 μM; 2 h) citrate reduces electrically evoked ACh release from Torpedo marmorata electric organ slices in a concentration-dependent manner, without altering ACh synthesis or compartmentation at 50 μM^[1].
Cetiedil (10 μM; 10 min) citrate does not affect ACh synthesis or endogenous ACh compartmentation in Torpedo marmorata electric organ synaptosomes, but it significantly reduces incorporation of newly synthesized radioactive ACh into synaptic vesicles^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

541.65

C₂₆H₃₉NO₉S

16286-69-4

O=C(OCCN1CCCCCC1)C(C2=CSC=C2)C3CCCCC3.OC(CC(C(O)=O)(O)CC(O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gaudry-Talarmain YM, et al. Cetiedil, a drug that inhibits acetylcholine release in Torpedo electric organ. J Neurochem. 1987 Aug;49(2):548-54.
  

  [2]. Abu-Salah KM, Gambo AH. An analysis of the mechanism by which cetiedil inhibits sickling. Life Sci. 2002 Jan 18;70(9):1003-11.
  

  [3]. Roxburgh CJ, et al. The synthesis and some pharmacological actions of the enantiomers of the K(+)-channel blocker cetiedil. J Pharm Pharmacol. 1996 Aug;48(8):851-7.